- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03096431
Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
Does Cognitive Rehabilitation and Physical Activity Impact Executive Functioning Following Radiation Therapy for Cerebral Metastases? A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0037
- Virginia Commonwealth University/Massey Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A potential subject must meet all of the following inclusion criteria to be eligible to participate in the study:
- Ability to understand and the willingness to provide written informed consent
- 18 years of age and older
- Diagnosed with one or more metastatic brain tumor(s)
- Medical treatment plan includes whole-brain radiation therapy and / or sterotactic radiosurgery
Exclusion Criteria:
- A potential subject who meets any of the following exclusion criteria is ineligible to participate in the study.
- Diagnosis of dementia or unable to grant their own informed consent
- Prisoner or patient in custody
- Patient on psychiatric hold
- Physically unable to participate in the study
- The opinion of the treating physician determines it is not medically safe to participate in the study
- Pre-registration screen of cognition is "severe" or lower.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1: Physical activity intervention
Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
Arm 1: intervention of physical activity begins.
60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
|
Other Names:
|
Active Comparator: Arm 2:Physical activity and cognitive intervention
Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
Arm 2: intervention of both cognitive rehabilitation and physical activity begins.
60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
|
Other Names:
One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
Other Names:
|
Active Comparator: Arm 3: Cognitive and begin physical activity intervention
Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment.
14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity.
60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
|
Other Names:
One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment percentage of eligible subjects.
Time Frame: 18.5 months
|
Recruitment: success defined as enrollment rate of 19% of eligible subjects.
|
18.5 months
|
Retention percentage of participants at end-of-study.
Time Frame: 18.5 months
|
Retention: success defined as retention rate above 56% at end-of-study.
|
18.5 months
|
Non-attendance rates of participants. instructions.
Time Frame: 18.5 months
|
Participant missed or cancelled therapy sessions less than 15% of time.
|
18.5 months
|
Lengths of sessions completed.
Time Frame: 18.5 months
|
Participant completed full scheduled minutes per session ≥ 80% of time.
|
18.5 months
|
Percentage of completion of Physical Activity intervention tasks.
Time Frame: 18.5 months
|
Participant completed ≥ 80% of PA interventions (required < 20% rest period during or between tasks).
|
18.5 months
|
Percentage of Cognitive Therapy intervention tasks.
Time Frame: 18.5 months
|
Participant completed ≥ 80% of CR interventions (required < 20% rest period during or between tasks).
|
18.5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive abilities.
Time Frame: 18.5 months
|
Composite score post-CR intervention, minus the composite score at baseline. Scores of zero indicates maintained cognition. Positive scores indicate improved cognition. Negative scores indicate declined cognition. Composite scores derived from the following four standardized tests:
|
18.5 months
|
Change in physical abilities.
Time Frame: 18.5 months
|
Composite scores post intervention minus scores at baseline. Scores of zero indicate maintained physical abilities. Positive scores indicate improved physical abilities. Negative scores indicate declined physical abilities. Composite scores derived from the following two standardized tests:
|
18.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suzanne F. Taylor, PhD, MBA, OTR/L, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-16-13082
- HM20007924 (Other Identifier: IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Brain Tumor
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
University of NebraskaArbor Pharmaceuticals, Inc.RecruitingBrain Tumor - MetastaticUnited States
-
Pietro Mortini, MD, Prof.RecruitingBrain Tumor, Primary | Brain Tumor - MetastaticItaly
-
Swedish Medical CenterUnknownMetastatic Brain TumorUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingSolid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic TumorUnited States
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomCompletedBone Metastases | Brain Metastases | Brain Tumor, Primary | Brain Tumor Adult | Brain Tumor - MetastaticUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterRecruitingBrain Tumor | Metastatic Brain TumorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Eisai Inc.CompletedPrimary Brain Tumor | Metastatic Malignant Neoplasm in the Adult BrainUnited States
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
Clinical Trials on Physical Activity
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Centre Hospitalier Departemental VendeeTerminated
-
Rio de Janeiro State UniversityCompleted
-
University of California, San DiegoRecruitingCognitive Change | Aging | Mild Cognitive Impairment | Cognitive Decline | Memory Disorders | Memory Impairment | Cognition Disorders in Old Age | Aging Problems | Memory Loss | Memory Disorders in Old Age | Memory Disorder, SpatialUnited States